- Home
- SUPN vs TENB Comparison
SUPN vs TENB Comparison
Compare SUPN & TENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SUPN | TENB |
|---|---|---|
| Founded | 2005 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.1B |
| IPO Year | 2010 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SUPN | TENB |
|---|---|---|
| Price | $48.27 | $35.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 18 |
| Target Price | ★ $61.60 | $31.69 |
| AVG Volume (30 Days) | 919.1K | ★ 3.4M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.23 |
| EPS | N/A | ★ 0.05 |
| Revenue | $392,755,000.00 | ★ $999,405,000.00 |
| Revenue This Year | $22.70 | $9.37 |
| Revenue Next Year | $19.14 | $7.04 |
| P/E Ratio | ★ N/A | $766.60 |
| Revenue Growth | N/A | ★ 11.04 |
| 52 Week Low | $41.78 | $15.73 |
| 52 Week High | $59.68 | $43.67 |
Technical Indicators
Market Signals| Indicator | SUPN | TENB |
|---|---|---|
| Relative Strength Index (RSI) | 54.48 | 52.34 |
| Support Level | $47.58 | $25.99 |
| Resistance Level | $52.33 | $43.67 |
| Average True Range (ATR) | 2.42 | 2.29 |
| MACD | 0.21 | 0.20 |
| Stochastic Oscillator | 54.38 | 69.90 |
Price Performance
Historical ComparisonAbout SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
About TENB Tenable Holdings Inc.
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.